Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- LVTX
- Price
- 1.16
- Stock movement up
- +0.07 (6.42%)
- Company name
- LAVA Therapeutics NV
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 30.51M
- Ent value
- 53.91M
- Price/Sales
- 4.03
- Price/Book
- 0.92
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -65.27%
- 3 year return
- -34.08%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
LVTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 4.03 |
| Price to Book | 0.92 |
| EV to Sales | 7.12 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 26.30M |
| EPS (TTM) | -1.03 |
| FCF per share (TTM) | -1.05 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 7.57M |
| Gross profit (TTM) | 6.96M |
| Operating income (TTM) | -28.04M |
| Net income (TTM) | -27.64M |
| EPS (TTM) | -1.03 |
| EPS (1y forward) | -1.40 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 91.95% |
| Operating margin (TTM) | -370.26% |
| Profit margin (TTM) | -365.02% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 26.96M |
| Net receivables | 1.02M |
| Total current assets | 81.54M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 83.36M |
| Accounts payable | 2.81M |
| Short/Current long term debt | 6.29M |
| Total current liabilities | 15.20M |
| Total liabilities | 50.36M |
| Shareholder's equity | 32.99M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -28.26M |
| Capital expenditures (TTM) | 31.76K |
| Free cash flow (TTM) | -28.29M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -83.78% |
| Return on Assets | -33.16% |
| Return on Invested Capital | -70.66% |
| Cash Return on Invested Capital | -72.32% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.12 |
| Daily high | 1.16 |
| Daily low | 1.09 |
| Daily Volume | 72K |
| All-time high | 16.00 |
| 1y analyst estimate | 3.63 |
| Beta | 0.48 |
| EPS (TTM) | -1.03 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 19 May 2025 |
Downside potential
Loading...
Downside potential data
| LVTX | S&P500 | |
| Current price drop from All-time high | -92.75% | -12.04% |
| Highest price drop | -94.33% | -56.47% |
| Date of highest drop | 11 Feb 2025 | 9 Mar 2009 |
| Avg drop from high | -76.56% | -11.07% |
| Avg time to new high | 255 days | 12 days |
| Max time to new high | 1007 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
30.51M
Marketcap category
Small-cap
Description
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Employees
37
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page